Meals and Drug Administration in the forthcoming months.

Aeterna Zentaris completes AEZS-130 Phase 3 research for diagnosis of AGHD Company expects to file New Drug Software Aeterna Zentaris Inc. The Company is currently proceeding with complete analyses of the data and finding your way through a pre-New Drug Software meeting with the U.S . Meals and Drug Administration in the forthcoming months, which would be followed by the filing of a NDA for the sign up of AEZS-130 in the usa. ‘We desire to thank those involved with this project for their utmost dedication.

Aerocrine announces the positive outcome of its complaint against Medisoft in Germany Aerocrine AB today announced the positive outcome of it is complaint against Medisoft P.A.E. Filed at the District Court of Dusseldorf, Germany. The judgments could be appealed by Medisoft and Medisoft has announced to document invalidity proceedings against Aerocrine’s patents.